HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ANS-6637

Also Known As:

((4-(4-((2,6-dichlorobenzamido)methyl)phenyl)-2-oxopyridin-1(2H)-yl)methyl dihydrogen phosphate monohydrate

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Aepfelbacher, Julia: 1 article (12/2020)
2.	Bunn, Haden T: 1 article (12/2020)
3.	George, Jomy M: 1 article (12/2020)
4.	Kattakuzhy, Sarah: 1 article (12/2020)
5.	Kottilil, Shyamasundaran: 1 article (12/2020)
6.	Masur, Henry: 1 article (12/2020)
7.	Mathur, Poonam: 1 article (12/2020)
8.	McLaughlin, Mary: 1 article (12/2020)
9.	Proschan, Michael: 1 article (12/2020)
10.	Rosenthal, Elana: 1 article (12/2020)

Related Diseases

1.	Flushing 01/01/2020 - "Flushing was the most common adverse event (AE) associated with ANS-6637 (24 of 36 participants) compared with placebo (3 of 12). " 01/01/2020 - "The most common pharmacological response was flushing and an increase in HR, which are known effects of acetaldehyde accumulation and consistent with inhibition of ALDH2 with oral ANS-6637 in combination with alcohol. The results of this alcohol interaction study support further testing of ANS-6637 in individuals who consume alcohol heavily."
2.	Substance-Related Disorders (Drug Abuse) 12/01/2020 - "ANS-6637, a pro-drug of GS-548351, is a selective, reversible inhibitor of aldehyde dehydrogenase isoform 2 under development as an anticraving agent for the treatment of substance use disorders. "
3.	Alcoholism (Alcohol Abuse) 01/01/2020 - "ANS-6637, an orally bioavailable selective and reversible aldehyde dehydrogenase-2 (ALDH2) inhibitor, is under development for drug and alcohol use disorders. "

Related Drugs and Biologics

1.	Acetaldehyde
2.	Protein Isoforms (Isoforms)
3.	Prodrugs
4.	Aldehydes
5.	Aldehyde Dehydrogenase
6.	GS-548351